1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-4045
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVernaz, Nathalie-
dc.contributor.authorGirardin, François-
dc.contributor.authorGoossens, Nicolas-
dc.contributor.authorBrügger, Urs-
dc.contributor.authorRiguzzi, Marco-
dc.contributor.authorPerrier, Arnaud-
dc.contributor.authorNegro, Francesco-
dc.date.accessioned2018-11-16T09:05:15Z-
dc.date.available2018-11-16T09:05:15Z-
dc.date.issued2016-
dc.identifier.issn1932-6203de_CH
dc.identifier.issn1932-6203de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/12886-
dc.description.abstractObjective: We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. We identified the following five steps in the development of HCV treatment regimens: 1) interferon (IFN)-α monotherapy in the early '90s, 2) IFN-α in combination with ribavirin (RBV), 3) pegylated (peg) IFN-α in combination with RBV, 4) the first direct acting antivirals (DAAs) (telaprevir and boceprevir) in combination with pegIFN- α and RBV, and 5) newer DAA-based regimens, such as sofosbuvir (which is or is not combined with ledipasvir) and fixed-dose combination of ritonavir-boosted paritaprevir and ombitasvir in combination with dasabuvir. Design: We performed a linear regression and mean cost analysis to test for an association between SVRs and HCV regimen prices. We conducted a sensitivity analysis using US prices at the time of US drug licensing. We selected randomized clinical trials of drugs approved for use in Switzerland from 1997 to July 2015 including treatment-naïve patients with HCV genotype 1 infection. Results: We identified a statistically significant positive relationship between the proportion of patients achieving SVRs and the costs of HCV regimens in Switzerland (with a bivariate ordinary least square regression yielding an R2 measure of 0.96) and the US (R2 = 0.95). The incremental cost per additional percentage of SVR was 597.14 USD in Switzerland and 1,063.81 USD in the US. Conclusion: The pricing of drugs for HCV regimens follows a value-based model, which has a stable ratio of costs per achieved SVR over 25 years. Health care systems are struggling with the high resource use of these new agents despite their obvious long-term advantages for the overall health of the population. Therefore, the pharmaceutical industry, health care payers and other stakeholders are challenged with finding new drug pricing schemes to treat the entire population infected with HCV.de_CH
dc.language.isoende_CH
dc.publisherPublic Library of Sciencede_CH
dc.relation.ispartofPLOS ONEde_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectAntiviral agentde_CH
dc.subjectCost-benefit analysisde_CH
dc.subjectDrug discoveryde_CH
dc.subjectDrug therapyde_CH
dc.subjectGenotypede_CH
dc.subjectHepacivirusde_CH
dc.subjectHepatitis Cde_CH
dc.subjectHumande_CH
dc.subjectInterferonde_CH
dc.subjectOligopeptidede_CH
dc.subjectRibavirinde_CH
dc.subjectRitonavirde_CH
dc.subjectSofosbuvirde_CH
dc.subjectSwitzerlandde_CH
dc.subjectUnited Statesde_CH
dc.subjectDrug pricingde_CH
dc.subject.ddc338: Produktionde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.titleDrug pricing evolution in Hepatitis Cde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
dc.identifier.doi10.21256/zhaw-4045-
dc.identifier.doi10.1371/journal.pone.0157098de_CH
zhaw.funding.euNode_CH
zhaw.issue6de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end12de_CH
zhaw.pages.start1de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume2016de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
File Description SizeFormat 
Drug Pricing Evolution_2016_SC1.1.PDF780.56 kBAdobe PDFThumbnail
View/Open
Show simple item record
Vernaz, N., Girardin, F., Goossens, N., Brügger, U., Riguzzi, M., Perrier, A., & Negro, F. (2016). Drug pricing evolution in Hepatitis C. Plos One, 2016(6), 1–12. https://doi.org/10.21256/zhaw-4045
Vernaz, N. et al. (2016) ‘Drug pricing evolution in Hepatitis C’, PLOS ONE, 2016(6), pp. 1–12. Available at: https://doi.org/10.21256/zhaw-4045.
N. Vernaz et al., “Drug pricing evolution in Hepatitis C,” PLOS ONE, vol. 2016, no. 6, pp. 1–12, 2016, doi: 10.21256/zhaw-4045.
VERNAZ, Nathalie, François GIRARDIN, Nicolas GOOSSENS, Urs BRÜGGER, Marco RIGUZZI, Arnaud PERRIER und Francesco NEGRO, 2016. Drug pricing evolution in Hepatitis C. PLOS ONE. 2016. Bd. 2016, Nr. 6, S. 1–12. DOI 10.21256/zhaw-4045
Vernaz, Nathalie, François Girardin, Nicolas Goossens, Urs Brügger, Marco Riguzzi, Arnaud Perrier, and Francesco Negro. 2016. “Drug Pricing Evolution in Hepatitis C.” Plos One 2016 (6): 1–12. https://doi.org/10.21256/zhaw-4045.
Vernaz, Nathalie, et al. “Drug Pricing Evolution in Hepatitis C.” Plos One, vol. 2016, no. 6, 2016, pp. 1–12, https://doi.org/10.21256/zhaw-4045.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.